Apr. 28 at 11:58 AM
$ACRS The drug showed an estimated half-life of ~45 days, unlocking the potential for up to a three-month dosing interval — that’s a significant competitive differentiator if it holds in disease populations. Quarterly dosing is a major convenience advantage over current standard-of-care biologics like dupilumab (Dupixent), which is dosed every two weeks.
Complete and sustained inhibition of both TSLP-induced and IL-4-induced CCL17/TARC was maintained through at least 20 weeks post-last dose for TSLP and 12 weeks for IL-4 — that’s durable pharmacodynamic coverage. No conjunctivitis signals is also notable, since that’s a known side effect with dupilumab that physicians and patients often flag.
The dual mechanism (blocking both TSLP and IL-4Rα) is an interesting bet — TSLP sits upstream in the inflammatory cascade, and IL-4Rα blockade catches downstream IL-4 and IL-13. Whether this translates to better efficacy than single-target agents remains unproven, but the science is rational.
